Omnicell Inc. reported first‑quarter 2026 results that surpassed expectations, delivering a non‑GAAP earnings per share of $0.55 versus the consensus estimate of $0.33, a $0.22 or 66.7% beat. Total revenue reached $309.9 million, up 15% from $270 million in Q1 2025 and beating the consensus estimate of $303.2 million by $6.7 million.
Revenue growth was driven by a 20% increase in product revenue to $174.8 million and an 8% rise in service revenue to $135.1 million, reflecting strong demand for Omnicell’s connected‑devices portfolio and core points‑of‑care solutions. The company also returned to profitability, reporting GAAP net income of $11.4 million (vs. a $7 million loss in Q1 2025) and non‑GAAP net income of $25 million, up from $12 million in the prior year.
Operating leverage and a favorable product mix lifted non‑GAAP gross margin to 46% in Q1 2026 from 42% in Q1 2025, while non‑GAAP EBITDA rose to $45 million, up from $24 million a year earlier. The margin expansion was largely attributable to disciplined cost management and the higher mix of higher‑margin product sales.
Management raised its full‑year 2026 guidance, projecting total revenue of $1.215 billion to $1.255 billion, non‑GAAP EBITDA of $153 million to $168 million, and non‑GAAP EPS of $1.80 to $2.00. The upward revision reflects confidence in continued demand, the momentum of the Titan XT automated dispensing system launch, and the growing share of recurring revenue from SaaS offerings.
CEO Randall Lipps said, “We started 2026 with solid execution in the first quarter, delivering results at the high end or above our previously issued Q1 2026 guidance ranges across all key metrics, which we believe reinforces the durability of our business model.” CFO Peter Kuipers added, “For the first quarter of 2026, non‑GAAP gross margin was approximately 46% compared to 42% in the first quarter of 2025, driven primarily by favorable mix and execution improvements across both product and services.”
Investors reacted positively to the earnings release, citing the substantial EPS beat and the raised full‑year guidance as evidence of strong execution and confidence in future growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.